COST EFFECTIVENESS ANALYSIS PENGGUNAAN CAPTOPRIL DAN AMLODIPIN PADA PASIEN HIPERTENSI PRIMER DI PUSKESMAS BANTUL I
Abstract
Hypertension is a disease called sillent killer, its mean this disease
can kill without causing symptoms. Hipertension in the long term can cause
complications to other organs. Treatment of primary hypertension is carried
out with long-term therapy even for a lifetime to get a better quality of life
besides hypertension has a fairly high prevalence rate so that the burden of
costs incurred will also be even greater. This study aims to determine the
results of the study of Cost Effectiveness Analysis of antihypertensive use of
Captopril and Amlodipine according to the perspective of health care
providers in primary hypertensive patients at the Bantul I Health Center.
This study uses a retrospective cohort design with total sampling data
collection techniques. Retrieval of data from medical records of primary
hypertensive patients on outpatient care in Bantul I Health Center. Subjects
were patients taking Captopril and Amlodipine single antihypertensive of 156
patients. Data analysis in this study using univariate analysis in the form of
average costs and effectiveness and pharmacoeconomic analysis in the form of
ACER and ICER values. The average cost used according to the perspective of
health care providers is taken from the antihypertensive costs needed to
achieve effectiveness while the average effectiveness is the percentage of
patients who reach the normal target in the range of 2-4 weeks.
The average cost of Amlodipine 5 mg is Rp. 29,520 and Captopril 25
mg is Rp. 11,133.33 and the average effectiveness of Amlodipine 5 mg is
59.06% and Captopril 25 mg is 50%, so the ACER value for Amlodipine 5 mg
Rp.499.83 and Captopril 25 mg is Rp222.66. ACER results showed that
Amlodipine 5 mg and Captopril 25 mg needed ICER calculation because
Amlodipin 5 mg had high effectiveness at high cost and Captopril 25 mg had
low effectiveness at low cost. The ICER results in Amlodipine 5 mg with the
antihypertensive alternative Captopril 25 mg were Rp2,029.43. So it takes
additional expenses Rp2.029,43 for each 1% increase in effectiveness of
Captopril 25 mg.